DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Canaccord Genuity Initiates Coverage On Neoleukin Therapeutics with Buy Rating, Announces $20 Price Target

Canaccord Genuity analyst Arlinda Lee initiates coverage on Neoleukin Therapeutics (NASDAQ:NLTX) with a Buy rating and a $20 price target.

Benzinga · 03/12/2020 10:46

Canaccord Genuity analyst Arlinda Lee initiates coverage on Neoleukin Therapeutics (NASDAQ:NLTX) with a Buy rating and a $20 price target.